Cell Therapy News

Bispecific T-cell engagers have induced impressive response rates among patients with relapsed or refractory multiple myeloma enrolled in early clinical trials.

Tumor gene expression profiles have become standard practice to help guide treatment of several cancer types.

Recent molecular science research may provide important insights as to why chimeric antigen receptor T-cell therapies for solid tumors have failed to achieve results that match those observed in blood cancers.

The FDA granted orphan drug designation to CT120, a novel chimeric antigen receptor T-cell therapy, for the treatment of B-cell acute lymphoblastic leukemia.

The FDA granted regenerative medicine advanced therapy designation to CTX110, a chimeric antigen receptor T-cell therapy in development for treatment of relapsed or refractory B-cell malignancies.

The FDA granted orphan drug designation to GC012F, a novel chimeric antigen receptor T-cell therapy for the treatment of relapsed or refractory multiple myeloma.

Half of patients with relapsed or refractory solid tumors achieved objective response to an infusion of IMA203, according to study results presented at Society for the Immunotherapy of Cancer Annual Meeting.

Patients with chronic kidney disease are not at an increased risk for AKI or death after chimeric antigen receptor T-cell therapy, according to a speaker at ASN Kidney Week.

Three patients have been safely treated with CT-0508, a novel cell-based therapy, according to initial results of a phase 1 trial presented at Society for the Immunotherapy of Cancer Annual Meeting.

Nearly a quarter of patients with heavily pretreated non-small cell lung cancer achieved an objective response to an infusion of LN-145, according to study results presented at Society for the Immunotherapy of Cancer Annual Meeting.